Literature DB >> 7574940

Perioperative donor bone marrow infusion augments chimerism in heart and lung transplant recipients.

S M Pham1, R J Keenan, A S Rao, P A Fontes, R L Kormos, K Abu-Elmagd, A Zeevi, A Kawai, B G Hattler, R L Hardesty.   

Abstract

BACKGROUND: We and others have demonstrated that a low level of donor cell chimerism was present for years after transplantation in tissues and peripheral blood of heart and lung recipients; it was associated, in the latter, with a lower incidence of chronic rejection. To augment this phenomenon, we initiated a trial combining simultaneous infusion of donor bone marrow with heart or lung allotransplantation.
METHODS: Between September 1993 and January 1995, 15 nonconditioned patients received either heart (n = 10) or lung (n = 5) allografts concurrently with an infusion of unmodified donor bone marrow (3.0 x 10(8) cells/kg), and were maintained on immunosuppressive regimen consisting of tacrolimus and steroids.
RESULTS: There was no complication associated with the infusion of donor bone marrow. Chimerism was detectable in 73% of bone marrow-augmented patients up to the last sample tested. Of the 5 control recipients who did not receive bone marrow infusion, only 1 had detectable chimerism by flow on postoperative day 15, which dwindled to an undetectable level by postoperative day 36. None of the patients had evidence of donor-specific immune modulation by mixed lymphocyte reaction.
CONCLUSIONS: The combined infusion of donor bone marrow and heart or lung transplantation, without preconditioning of the recipient, is safe and is associated with an augmentation of donor cell chimerism.

Entities:  

Mesh:

Year:  1995        PMID: 7574940      PMCID: PMC2967193          DOI: 10.1016/0003-4975(95)00579-a

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  18 in total

Review 1.  Cell migration, chimerism, and graft acceptance.

Authors:  T E Starzl; A J Demetris; N Murase; S Ildstad; C Ricordi; M Trucco
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation.

Authors:  G J Berry; E M Brunt; D Chamberlain; R H Hruban; R K Sibley; S Stewart; H D Tazelaar
Journal:  J Heart Transplant       Date:  1990 Nov-Dec

3.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.

Authors:  M E Billingham; N R Cary; M E Hammond; J Kemnitz; C Marboe; H A McCallister; D C Snovar; G L Winters; A Zerbe
Journal:  J Heart Transplant       Date:  1990 Nov-Dec

Review 4.  Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.

Authors:  T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

5.  Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts.

Authors:  S T Ildstad; D H Sachs
Journal:  Nature       Date:  1984 Jan 12-18       Impact factor: 49.962

6.  Total lymphatic irradiation and bone marrow in human heart transplantation.

Authors:  D R Kahn; R Hong; A J Greenberg; E F Gilbert; G C Dacumos; J H Dufek
Journal:  Ann Thorac Surg       Date:  1984-08       Impact factor: 4.330

7.  Systemic chimerism in human female recipients of male livers.

Authors:  T E Starzl; A J Demetris; M Trucco; H Ramos; A Zeevi; W A Rudert; M Kocova; C Ricordi; S Ildstad; N Murase
Journal:  Lancet       Date:  1992-10-10       Impact factor: 79.321

8.  Clinical trial of FK 506 immunosuppression in adult cardiac transplantation.

Authors:  J M Armitage; R L Kormos; S Morita; J Fung; G C Marrone; R L Hardesty; B P Griffith; T E Starzl
Journal:  Ann Thorac Surg       Date:  1992-08       Impact factor: 4.330

9.  Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients.

Authors:  W H Barber; J A Mankin; D A Laskow; M H Deierhoi; B A Julian; J J Curtis; A G Diethelm
Journal:  Transplantation       Date:  1991-01       Impact factor: 4.939

10.  Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation.

Authors:  T E Starzl; A J Demetris; M Trucco; A Zeevi; H Ramos; P Terasaki; W A Rudert; M Kocova; C Ricordi; S Ildstad
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

View more
  5 in total

1.  Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients.

Authors:  A S Rao; P Fontes; F Dodson; A Zeevi; M T Rugeles; K Abu-Elmagd; A Aitouche; G Rosner; M Trucco; A J Demetris; W Rybka; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1996-10       Impact factor: 1.066

2.  Three years of follow-up of bone marrow-augmented organ transplant recipients: the impact on donor-specific immune modulation.

Authors:  A Zeevi; M Pavlick; R Banas; C Bentlejewski; K Spichty; A S Rao; P Fontes; A Iyengar; R Shapiro; F Dodson; M Jordan; S Pham; R Keenan; B Griffith; R Corry; F Egidi; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

3.  Clinical implementation of a procedure to prepare bone marrow cells from cadaveric vertebral bodies.

Authors:  Albert D Donnenberg; Vijay S Gorantla; Stefan Schneeberger; Linda R Moore; Gerald Brandacher; Heather M Stanczak; Eileen K Koch; Wp Andrew Lee
Journal:  Regen Med       Date:  2011-11       Impact factor: 3.806

4.  A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results.

Authors:  S M Pham; A S Rao; A Zeevi; R L Kormos; K R McCurry; B G Hattler; J J Fung; T E Starzl; B P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  2000-04       Impact factor: 5.209

5.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.